Risk willingness in multiple system atrophy and Parkinson’s disease understanding patient preferences

Abstract Disease-modifying therapeutics in the α-synucleinopathies multiple system atrophy (MSA) and Parkinson’s Disease (PD) are in early phases of clinical testing. Involving patients’ preferences including therapy-associated risk willingness in initial stages of therapy development has been incre...

Descripción completa

Detalles Bibliográficos

Autores principales:	Alexander Maximilian Bernhardt, Marc Oeller, Isabel Friedrich, Emre Kocakavuk, Eliana Nachman, Kevin Peikert, Malte Roderigo, Andreas Rossmann, Tabea Schröter, Lea Olivia Wilhelm, Tino Prell, Christoph van Riesen, Johanna Nieweler, Sabrina Katzdobler, Markus Weiler, Heike Jacobi, Tobias Warnecke, Inga Claus, Carla Palleis, Stephan Breimann, Björn Falkenburger, Moritz Brandt, Andreas Hermann, Jost-Julian Rumpf, Joseph Claßen, Günter Höglinger, Florin Gandor, Johannes Levin, Armin Giese, Annette Janzen, Wolfgang Hermann Oertel
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2024-08-01
Colección:	npj Parkinson's Disease
Acceso en línea:	https://doi.org/10.1038/s41531-024-00764-5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!